Immune cell therapy shows promise for tough lymphoma cases
NCT ID NCT03029338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a personalized cell therapy called CD19 CAR T cells in 20 adults with relapsed or refractory B-cell lymphoma. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. The main goals were to check safety and see if the cells could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19 CAR T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat B-cell lymphoma.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so results may not apply to everyone. Side effects from CAR T therapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMAS NON-HODGKIN'S B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Face shape may predict how teeth shift after braces
- AI model aims to predict ABPA relapse risk
- New hope for Early-Relapse colorectal cancer: immune booster added to chemo
- Simple blood test could predict transplant complications